Summary of PET-Only Studies
| Result | ||||
|---|---|---|---|---|
| Stage | 123I-MIBG > 18F-FDG | 18F-FDG > 123I-MIBG | Equivalent | Negative |
| Stage 1 neuroblastoma (5 scans/3 patients*) | ||||
| Diagnosis | — | 2 scans/2 pts | — | — |
| Follow-up | — | 3 scans/1 pt | — | — |
| Total | — | 5 scans/3 pts | — | — |
| Stage 4 neuroblastoma (8 scans/5 patients*) | ||||
| Diagnosis | 1 scan/1 pt | — | — | — |
| Follow-up ≤ 12 months | 1 scan/1 pt | — | — | — |
| Follow-up > 12 months | 2 scans/2 pts | 1 scan/1 pt | 1 scan/1 pt | 2 scans/2 pts |
| Total | 4 scans/4 pts | 1 scan/1 pt | 1 scan/1 pt | 2 scans/2 pts |
↵* Patients with more than 1 scan during study period may be listed in different categories (i.e., patients scanned at both diagnosis and follow-up or patients with multiple follow-up scans with different results).
123I-MIBG > 18F-FDG = numbers of scans and patients for which 123I-MIBG detected more lesions; pts = patients; 18F-FDG > 123I-MIBG = numbers of scans and patients for which 18F-FDG detected more lesions; Equivalent = numbers of scans and patients for which 123I-MIBG and 18F-FDG detected similar or complementary numbers and distributions of lesions; Negative = numbers of scans and patients for which 123I-MIBG and 18F-FDG study results were normal.